Abstract
Although the outcomes have improved in metastatic castrate-resistant prostate cancer (mCRPC), there is a limited arsenal of treatment options at the oncologist's disposal. The options range from enzalutamide and abiraterone (hormone-based therapies), docetaxel and cabazitaxel (chemotherapy), and radium-223 (radioactive isotope), but beyond these medications there are no other options and additionally none of these options are curative.1 Next Generation Sequencing (NGS), including Guardant360, allows clinicians to sequence tumor tissues or blood samples in a short timeframe. The use of NGS for patients is a new outlet to identify therapies that would otherwise not be selected when potentially appropriate. The NGS platform Guardant360 constructs a genomic profile by analyzing 72 somatic cancer-associated genes from circulating tumor DNA (ctDNA) derived from serum. The implications of the data from NGS can be used to guide treatment with the potential for finding a sui generis target within a tumor sample giving patients personalized therapeutic options. Herein, we discuss a case of mCRPC treated with a targeted therapy based on the patient's ctDNA results and provide insight into the future considerations for NGS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
